Rituximab (anti-CD20 monoclonal antibody) for refractory systemic lupus erythematosus. Report of one case;Uso de rituximab (anticuerpo monoclonal anti-CD20) en lupus eritematoso sistémico refractario a tratamiento: Caso clínico

Revista Medica de Chile

Volumn 133, Issue 6, 2005, Pages 681-684

  Sabugo S, Francisca ^a   Llanos M, Carolina ^a   Soto S, Lilian ^a   Gutiérrez, Jorge ^b   Cuchacovich T, Miguel ^a,b,c  

^a HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

^b CLÍNICA LAS CONDES   (Chile)

^c Oficina 607   (Chile)

Author keywords

Lupus erythematosus, systemic; Monoclonal antibody CD20; Rituximab

Indexed keywords

IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; RITUXIMAB;

ADOLESCENT; ARTICLE; CASE REPORT; FEMALE; HUMAN; IMMUNOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 27744584591     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. PISETSKY D. Systemic lupus erithematosus. Epidemiology, pathology and pathogenesis. En: Klippel JH, ed. Primer on the rheumatic diseases. Atlanta, Georgia: Arthritis Foundation, 2001.
2. REEVES GE. Update on the immunology, diagnosis and management of systemic lupus erythematosus. Intern Med J 2004; 34: 338-47.
3. REFF M, CARNER K, CHAMBERS K, CHINN P, LEONARD J, RAAB R ET AL. Depletion of B Cells in vivo by chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-45.
4. LOONEY RJ, ANOLIK JH, CAMPBELL D, FELGAR R, YOUNG F, AREND L ET AL. B cell depletion as a novel treatment for systemic lupus erithematosus: A phase I/II dose- escalation trial of Rituximab. Arthritis Rheum 2004; 50: 2580-9.
5. ANOLIK JH, BARNARD J, CAPPIONE A, PUGH-BERNARD A, FELGAR R, LOONEY RJ ET AL. Rituximab improves peripheral B cell abnormalities un human systemic lupus erythematosus. Arthritis Rheum 2004; 50: 3580-90.
6. LOONEY RJ, ANOLIK JH, SANZ I. B cells as therapeutic targets for rheumatic diseases. Curr Opin Rheumatol 2004; 16: 180-5.
7. HAINSWORTH J. Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis. Arthritis Res Ther 2003; 5 Suppl 4: S12-6.
8. LEANDRO MJ, EDWARDS J, CAMBRIDGE G, EHRENSTEIN MR, ISENBERG DA. An open study of B lymphocyte depletion in systemic lupus erythematosous. Arthritis Rheum 2002; 46: 2773-7.
9. CATE R, SMIERS F, BREDIUS M, LANKESTER A, SUIJLEKMON-SMIT L, HUIZINGA T ET AL. Anti-CD20 monoclonal antibody (rituximab) for refractory autoimmune thrombocytopenia in a girl with systemic lupus erythematosous. Rheumatol 2004; 43: 244.
10. PERROTTA S, LOCATELLI F, LA MANNA, CENNAMO L, DE STEFANO P, NOBILI BRUNO. Anti-CD20 monoclonal antibody (rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosous. Br J Haematol 2002; 116: 465-7.